

Supplemental References

1. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. *Cancer immunity*. 2008;8:9.
2. Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. *Cancer immunology, immunotherapy : CII*. 2009;58(8):1297-306. doi:<https://dx.doi.org/10.1007/s00262-008-0642-y>
3. Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2009;32(3):322-4. doi:<https://dx.doi.org/10.1097/CJI.0b013e31819aa40b>
4. Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. *Medical oncology (Northwood, London, England)*. 2011;28(4):1140-4. doi:<https://dx.doi.org/10.1007/s12032-010-9606-0>
5. Manousakis G, Koch J, Somerville RB, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. *Muscle & nerve*. 2013;48(3):440-4. doi:<https://dx.doi.org/10.1002/mus.23830>
6. Tissot C, Carsin A, Freymond N, Pacheco Y, Devouassoux G. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. *Eur Respir J*. Jan 2013;41(1):246-7. doi:10.1183/09031936.00107912
7. Dick J, Enk A, Hassel JC. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy? *Dermatology (Basel, Switzerland)*. 2015;230(1):8-10. doi:<https://dx.doi.org/10.1159/000365078>
8. Johnson DB, Friedman DL, Berry E, et al. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. *Cancer immunology research*. 2015;3(5):464-9. doi:<https://dx.doi.org/10.1158/2326-6066.CIR-14-0217>
9. Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. *Oncogene*. 2015;34(43):5411-7. doi:<https://dx.doi.org/10.1038/onc.2015.5>
10. Jinnur P, Lim KG. Severe Acute Orthopnea: Ipilimumab-Induced Bilateral Phrenic Nerve Neuropathy. *Lung*. 2015;193(4):611-3. doi:<https://dx.doi.org/10.1007/s00408-015-9716-8>
11. Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. *The American journal of surgical pathology*. 2015;39(8):1075-84. doi:<https://dx.doi.org/10.1097/PAS.0000000000000453>
12. Altman AL, Golub JS, Pensak ML, Samy RN. Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma. *Otolaryngol Head Neck Surg*. Nov 2015;153(5):894-5. doi:10.1177/0194599815606701
13. Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. *J Neuroophthalmol*. Jun 2015;35(2):144-7. doi:10.1097/WNO.0000000000000217
14. Abdallah A-O, Herlopian A, Ravilla R, et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2016;22(3):537-42. doi:<https://dx.doi.org/10.1177/1078155215572932>
15. Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo A-M. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature. *Ocular immunology and inflammation*. 2016;24(2):140-6. doi:<https://dx.doi.org/10.3109/09273948.2014.1001858>
16. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22(4):886-94. doi:<https://dx.doi.org/10.1158/1078-0432.CCR-15-1136>
17. Khoja L, Maurice C, Chappell M, et al. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. *Cancer immunology research*. 2016;4(3):175-8. doi:<https://dx.doi.org/10.1158/2326-6066.CIR-15-0186>
18. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. *Cancer immunology research*. 2016;4(5):383-9. doi:<https://dx.doi.org/10.1158/2326-6066.CIR-15-0123>
19. Hwang SJE, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. *Melanoma research*. 2016;26(4):413-6. doi:<https://dx.doi.org/10.1097/CMR.0000000000000260>

20. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. *European journal of cancer (Oxford, England : 1990)*. 2016;60:210-25. doi:<https://dx.doi.org/10.1016/j.ejca.2016.02.024>
21. Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. *Journal for immunotherapy of cancer*. 2016;4:20. doi:<https://dx.doi.org/10.1186/s40425-016-0123-3>
22. Bowyer S, Prithviraj P, Lorigan P, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. *British journal of cancer*. 2016;114(10):1084-9. Comment in: *Br J Cancer*. 2017 Apr 11;116(8):e14; PMID: 28324884 [<https://www.ncbi.nlm.nih.gov/pubmed/28324884>][[Comment](https://www.ncbi.nlm.nih.gov/pubmed/28324884) in: *Br J Cancer*. 2017 Apr 11;116(8):e15; PMID: 28324885 [<https://www.ncbi.nlm.nih.gov/pubmed/28324885>]. doi:<https://dx.doi.org/10.1038/bjc.2016.107>
23. Chia PL, John T. Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2016;39(5):202-4. doi:<https://dx.doi.org/10.1097/CJI.0000000000000121>
24. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. *Annals of the rheumatic diseases*. 2017;76(1):43-50. Comment in: *Ann Rheum Dis*. 2017 Jan;76(1):1-3; PMID: 27566797 [<https://www.ncbi.nlm.nih.gov/pubmed/27566797>]. doi:<https://dx.doi.org/10.1136/annrheumdis-2016-209595>
25. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. *Cancer science*. 2016;107(7):1055-8. doi:<https://dx.doi.org/10.1111/cas.12961>
26. Gounant V, Brosseau S, Naltet C, et al. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. *Lung cancer (Amsterdam, Netherlands)*. 2016;99:162-5. doi:<https://dx.doi.org/10.1016/j.lungcan.2016.07.010>
27. Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ipilimumab-Induced Neutropenia in Melanoma. *Journal of investigative medicine high impact case reports*. 2016;4(3):2324709616661835. doi:<https://dx.doi.org/10.1177/2324709616661835>
28. Ascierto PA, Vanella V, Grimaldi AM, et al. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. *Cancer immunology, immunotherapy : CII*. 2016;65(11):1395-1400.
29. Uemura M, Fa'ak F, Haymaker C, et al. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. *Journal for immunotherapy of cancer*. 2016;4:55. Erratum in: *J Immunother Cancer*. 2017 Jan 18;5:7; PMID: 28116090 [<https://www.ncbi.nlm.nih.gov/pubmed/28116090>]. doi:<https://dx.doi.org/10.1186/s40425-016-0157-6>
30. Diem S, Keller F, Ruesch R, et al. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2016;39(9):379-382.
31. Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. *Journal for immunotherapy of cancer*. 2016;4:66.
32. Abe J, Sato T, Tanaka R, Okazaki T, Takahashi S. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient. *The American journal of case reports*. 2016;17:880-882.
33. Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. *BMC Nephrol*. Nov 22 2016;17(1):188. doi:10.1186/s12882-016-0408-2
34. Parakh S, Nguyen R, Opie JM, Andrews MC. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. *The Australasian journal of dermatology*. 2017;58(3):e109-e112. doi:<https://dx.doi.org/10.1111/ajd.12488>
35. Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *Journal of hepatology*. 2017;66(3):545-551. Comment in: *J Hepatol*. 2017 Mar;66(3):482-484; PMID: 28011330 [<https://www.ncbi.nlm.nih.gov/pubmed/28011330>]. doi:<https://dx.doi.org/10.1016/j.jhep.2016.10.029>
36. Spain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. *Cancer immunology, immunotherapy : CII*. 2017;66(1):113-117. doi:<https://dx.doi.org/10.1007/s00262-016-1926-2>
37. Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. *The British journal of dermatology*. 2017;176(6):1649-1652. Comment in: *Br J Dermatol*. 2017 Jun;176(6):1444-1445; PMID: 28581240 [<https://www.ncbi.nlm.nih.gov/pubmed/28581240>]. doi:<https://dx.doi.org/10.1111/bjd.15237>
38. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. *The American Journal of dermatopathology*. 2017;39(2):121-129. doi:<https://dx.doi.org/10.1097/DAD.0000000000000688>
39. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. *Cancer immunology, immunotherapy : CII*. 2017;66(5):581-592. doi:<https://dx.doi.org/10.1007/s00262-017-1962-6>

40. Shiuan E, Beckermann KE, Ozgun A, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. *Journal for immunotherapy of cancer*. 2017;5:8. doi:<https://dx.doi.org/10.1186/s40425-017-0210-0>
41. Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2017;28(2):377-385. Comment in: *Ann Oncol*. 2017 Feb 1;28(2):204-205; PMID: 27993803 [<https://www.ncbi.nlm.nih.gov/pubmed/27993803>]. doi:<https://dx.doi.org/10.1093/annonc/mdw558>
42. Larkin J, Chmielowski B, Lao CD, et al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. *The oncologist*. 2017;22(6):709-718. doi:<https://dx.doi.org/10.1634/theoncologist.2016-0487>
43. Kanno H, Ishida K, Yamada W, et al. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2017;23(11):774-777. doi:<https://dx.doi.org/10.1016/j.jiac.2017.04.007>
44. Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. *Lung cancer (Amsterdam, Netherlands)*. 2017;109:42-44. doi:<https://dx.doi.org/10.1016/j.lungcan.2017.04.019>
45. Ruiz-Banobre J, Perez-Pampin E, Garcia-Gonzalez J, et al. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. *Lung cancer (Amsterdam, Netherlands)*. 2017;108:217-221. doi:<https://dx.doi.org/10.1016/j.lungcan.2017.04.007>
46. Kaunitz GJ, Loss M, Rizvi H, et al. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. *The American journal of surgical pathology*. 2017;41(10):1381-1389. doi:<https://dx.doi.org/10.1097/PAS.0000000000000900>
47. Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. *Annals of the rheumatic diseases*. 2017;76(12):2061-2064. doi:<https://dx.doi.org/10.1136/annrheumdis-2017-211560>
48. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, et al. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy- Report of 2 patients. *Journal of cutaneous pathology*. 2017;44(12):1080-1086. doi:<https://dx.doi.org/10.1111/cup.13044>
49. Brouwer NJ, Haanen JBAG, Jager MJ. Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. *Ocular oncology and pathology*. 2017;3(3):188-192. doi:<https://dx.doi.org/10.1159/000455150>
50. Hsieh AH-C, Faithfull S, Brown MP. Risk of cumulative toxicity after complete melanoma response with pembrolizumab. *BMJ case reports*. 2017;2017doi:<https://dx.doi.org/10.1136/bcr-2016-218308>
51. Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. *ESMO open*. 2017;2(4):e000268. doi:<https://dx.doi.org/10.1136/esmoopen-2017-000268>
52. Balaji A, Verde F, Suresh K, Naidoo J. Pneumonitis From Anti-PD-1/ PD-L1 Therapy. *Oncology (Williston Park, NY)*. 2017;31(10):739-754.
53. e Chabot G, Justeau G, Pinquie F, et al. [Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases]. *Revue de pneumologie clinique*. 2017;73(6):326-330. doi:<https://dx.doi.org/10.1016/j.pneumo.2017.08.012>
54. Pfohler C, Eichler H, Burgard B, Krecke N, Muller CSL, Vogt T. A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma. *Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie*. 2017;44(6):426-428. doi:<https://dx.doi.org/10.1159/000479237>
55. Benson Z, Gordon S, Nicolato P, Poklepovic A. Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. *Case reports in oncological medicine*. 2017;2017:8095601. doi:<https://dx.doi.org/10.1155/2017/8095601>
56. Elosua-Gonzalez M, Pampin-Franco A, Mazzucchelli-Esteban R, et al. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. *Dermatology online journal*. 2017;23(8)
57. Alhammad RM, Dronca RS, Kottschade LA, et al. Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. *Mayo Clinic proceedings Innovations, quality & outcomes*. 2017;1(2):192-197. doi:<https://dx.doi.org/10.1016/j.mayocpiqo.2017.07.004>
58. Kitchlu A, Fingrut W, Avila-Casado C, et al. Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases. *Am J Kidney Dis*. Oct 2017;70(4):581-585. doi:10.1053/j.ajkd.2017.04.026
59. Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. *Clin Exp Dermatol*. Apr 2017;42(3):309-312. doi:10.1111/ced.13042
60. Michot JM, Vargaftig J, Leduc C, et al. Immune-related bone marrow failure following anti-PD1 therapy. *Eur J Cancer*. Jul 2017;80:1-4. doi:10.1016/j.ejca.2017.04.004

61. Narumi Y, Yoshida R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. *BMC cancer*. 2018;18(1):95. doi:<https://dx.doi.org/10.1186/s12885-018-3997-2>
62. Kostine M, Rouxel L, Barnette T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. *Annals of the rheumatic diseases*. 2018;77(3):393-398. Comment in: *Nat Rev Rheumatol*. 2018 Jan;14(1):1; PMID: 29213123 [<https://www.ncbi.nlm.nih.gov/pubmed/29213123>]Comment in: *Ann Rheum Dis*. 2019 Jul;78(7):e68; PMID: 29724725 [<https://www.ncbi.nlm.nih.gov/pubmed/29724725>]Comment in: *Ann Rheum Dis*. 2019 Jul;78(7):e70; PMID: 29760158 [<https://www.ncbi.nlm.nih.gov/pubmed/29760158>]Comment in: *Ann Rheum Dis*. 2019 Jul;78(7):e67; PMID: 29858173 [<https://www.ncbi.nlm.nih.gov/pubmed/29858173>]Comment in: *Ann Rheum Dis*. 2019 Jul;78(7):e71; PMID: 29925509 [<https://www.ncbi.nlm.nih.gov/pubmed/29925509>]Comment in: *Ann Rheum Dis*. 2019 Jul;78(7):e69; PMID: 29934372 [<https://www.ncbi.nlm.nih.gov/pubmed/29934372>]Comment in: *Ann Rheum Dis*. 2019 Aug;78(8):e82; PMID: 29936437 [<https://www.ncbi.nlm.nih.gov/pubmed/29936437>]Comment in: *Ann Rheum Dis*. 2019 Sep;78(9):e91; PMID: 29950326 [<https://www.ncbi.nlm.nih.gov/pubmed/29950326>]Comment in: *Ann Rheum Dis*. 2019 Sep;78(9):e92; PMID: 30100560 [<https://www.ncbi.nlm.nih.gov/pubmed/30100560>]. doi:<https://dx.doi.org/10.1136/annrheumdis-2017-212257>
63. Kishi S, Minato M, Saijo A, et al. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. *Internal medicine (Tokyo, Japan)*. 2018;57(9):1259-1263. doi:<https://dx.doi.org/10.2169/internalmedicine.9814-17>
64. Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. *Seminars in arthritis and rheumatism*. 2018;47(6):907-910. doi:<https://dx.doi.org/10.1016/j.semarthrit.2017.10.018>
65. McGuire HM, Shklovskaya E, Edwards J, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. *Cancer immunology, immunotherapy : CII*. 2018;67(4):563-573. doi:<https://dx.doi.org/10.1007/s00262-017-2107-7>
66. Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. *Journal of neuro-oncology*. 2018;137(3):601-609. doi:<https://dx.doi.org/10.1007/s11060-018-2752-5>
67. Kolb NA, Trevino CR, Waheed W, et al. Neuromuscular complications of immune checkpoint inhibitor therapy. *Muscle & nerve*. 2018;doi:<https://dx.doi.org/10.1002/mus.26070>
68. Luu Q, Major G. Unleashing the tiger - iatrogenic autoimmunity from cancer immunotherapy drugs. *JRSM open*. 2018;9(1):2054270417746905. doi:<https://dx.doi.org/10.1177/2054270417746905>
69. De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *Journal of hepatology*. 2018;68(6):1181-1190. Comment in: *J Hepatol*. 2018 Aug;69(2):548-550; PMID: 29747956 [<https://www.ncbi.nlm.nih.gov/pubmed/29747956>]Comment in: *J Hepatol*. 2018 Aug;69(2):550-551; PMID: 29776713 [<https://www.ncbi.nlm.nih.gov/pubmed/29776713>]Comment in: *J Hepatol*. 2018 Oct;69(4):976-978; PMID: 30093162 [<https://www.ncbi.nlm.nih.gov/pubmed/30093162>]Comment in: *J Hepatol*. 2018 Oct;69(4):978-979; PMID: 30097327 [<https://www.ncbi.nlm.nih.gov/pubmed/30097327>]Comment in: *J Hepatol*. 2018 Dec;69(6):1396-1397; PMID: 30292476 [<https://www.ncbi.nlm.nih.gov/pubmed/30292476>]Comment in: *J Hepatol*. 2018 Dec;69(6):1397-1398; PMID: 30297274 [<https://www.ncbi.nlm.nih.gov/pubmed/30297274>]Comment in: *J Hepatol*. 2019 Mar;70(3):564-566; PMID: 30503040 [<https://www.ncbi.nlm.nih.gov/pubmed/30503040>]Comment in: *J Hepatol*. 2019 Mar;70(3):566-567; PMID: 30527952 [<https://www.ncbi.nlm.nih.gov/pubmed/30527952>]. doi:<https://dx.doi.org/10.1016/j.jhep.2018.01.033>
70. Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. *Journal for immunotherapy of cancer*. 2018;6(1):14. doi:<https://dx.doi.org/10.1186/s40425-018-0323-0>
71. Matsubara T, Nishida T, Higaki Y, et al. Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma. *Internal medicine (Tokyo, Japan)*. 2018;57(12):1789-1792. doi:<https://dx.doi.org/10.2169/internalmedicine.9851-17>
72. Martini DJ, Hamieh L, McKay RR, et al. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. *Cancer immunology research*. 2018;6(4):402-408. doi:<https://dx.doi.org/10.1158/2326-6066.CIR-17-0220>
73. Inamo J, Kaneko Y, Takeuchi T. Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment. *Clinical rheumatology*. 2018;37(4):1107-1110. doi:<https://dx.doi.org/10.1007/s10067-018-4035-0>
74. Hid Cadena R, Abdulahad WH, Hoppers GAP, et al. Checks and Balances in Autoimmune Vasculitis. *Frontiers in immunology*. 2018;9:315. doi:<https://dx.doi.org/10.3389/fimmu.2018.00315>
75. Algaze SD, Park W, Harrington TJ, Mudar R. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. *BMJ case reports*. 2018;2018doi:<https://dx.doi.org/10.1136/bcr-2017-221801>
76. Acero Brand FZ, Suter N, Adam J-P, et al. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. *Journal for immunotherapy of cancer*. 2018;6(1):22. doi:<https://dx.doi.org/10.1186/s40425-018-0332-z>

77. Mandala M, Merelli B, Indriolo A, Tondini C. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. *European journal of cancer (Oxford, England : 1990)*. 2018;95:130-132. doi:<https://dx.doi.org/10.1016/j.ejca.2018.02.019>
78. Badovinac S, Korsic M, Zarkovic K, et al. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer. *Immunotherapy*. 2018;10(6):427-431. doi:<https://dx.doi.org/10.2217/imt-2017-0174>
79. Lomax AJ, Lim J, Cheng R, et al. Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. *Journal of skin cancer*. 2018;2018:9602540. doi:<https://dx.doi.org/10.1155/2018/9602540>
80. Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis. *Respirology case reports*. 2018;6(5):e00322. doi:<https://dx.doi.org/10.1002/rcr2.322>
81. Tjarks BJ, Kerkvliet AM, Jassim AD, Bleeker JS. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. *Journal of cutaneous pathology*. 2018;45(8):615-618. doi:<https://dx.doi.org/10.1111/cup.13273>
82. Mancone S, Lycan T, Ahmed T, et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. *Journal of neurology*. 2018;265(7):1636-1642. doi:<https://dx.doi.org/10.1007/s00415-018-8890-z>
83. Paolini L, Poli C, Blanchard S, et al. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. *Journal for immunotherapy of cancer*. 2018;6(1):52. doi:<https://dx.doi.org/10.1186/s40425-018-0372-4>
84. Chen W-S, Tetzlaff MT, Diwan H, et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. *Journal of cutaneous pathology*. 2018;45(10):764-773. doi:<https://dx.doi.org/10.1111/cup.13312>
85. Derle E, Benli S. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2018;39(10):1773-1774. doi:<https://dx.doi.org/10.1007/s10072-018-3471-6>
86. Tan I, Malinzak M, Salama AKS. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. *Journal for immunotherapy of cancer*. 2018;6(1):77. doi:<https://dx.doi.org/10.1186/s40425-018-0390-2>
87. Narvaez J, Juarez-Lopez P, Lluch J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. *Autoimmunity reviews*. 2018;17(10):1040-1045. doi:<https://dx.doi.org/10.1016/j.autrev.2018.05.002>
88. Garcia CA, El-Ali A, Rath TJ, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. *Journal for immunotherapy of cancer*. 2018;6(1):83. doi:<https://dx.doi.org/10.1186/s40425-018-0393-z>
89. Ortega Sanchez G, Jahn K, Savic S, Zippelius A, Laubli H. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. *Journal for immunotherapy of cancer*. 2018;6(1):85. doi:<https://dx.doi.org/10.1186/s40425-018-0400-4>
90. Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following Immune Checkpoint Inhibition. *Case reports in oncology*. 2018;11(2):521-526. doi:<https://dx.doi.org/10.1159/000491599>
91. Burotto M, Gormaz JG, Samtani S, et al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. *Seminars in oncology*. 2018;45(3):164-169. doi:<https://dx.doi.org/10.1053/j.seminoncol.2018.03.003>
92. Moseley KF, Naidoo J, Bingham CO, et al. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. *Journal for immunotherapy of cancer*. 2018;6(1):104. doi:<https://dx.doi.org/10.1186/s40425-018-0417-8>
93. Donaldson M, Owen JL, Chae YK, Choi JN. Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy. *Frontiers in oncology*. 2018;8:405. doi:<https://dx.doi.org/10.3389/fonc.2018.00405>
94. Comont T, Sibaud V, Mourey L, Cougoul P, Beyne-Rauzy O. Immune checkpoint inhibitor-related acral vasculitis. *Journal for immunotherapy of cancer*. 2018;6(1):120. Comment on: *J Immunother Cancer*. 2018 Feb 12;6(1):12; PMID: 29433584 [<https://www.ncbi.nlm.nih.gov/pubmed/29433584>]. doi:<https://dx.doi.org/10.1186/s40425-018-0443-6>
95. Delanoy N, Michot J-M, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. *The Lancet Haematology*. 2019;6(1):e48-e57. Comment in: *Lancet Haematol*. 2019 Jan;6(1):e10-e11; PMID: 30528136 [<https://www.ncbi.nlm.nih.gov/pubmed/30528136>]. doi:[https://dx.doi.org/10.1016/S2352-3026\(18\)30175-3](https://dx.doi.org/10.1016/S2352-3026(18)30175-3)
96. de Jong C, Peters BJM, Schramel FMNH. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer. *Chemotherapy*. 2018;63(5):272-277. doi:<https://dx.doi.org/10.1159/000494841>
97. Horisberger A, La Rosa S, Zurcher J-P, et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. *Journal for immunotherapy of cancer*. 2018;6(1):156. doi:<https://dx.doi.org/10.1186/s40425-018-0481-0>

98. Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer. *Case reports in neurology*. 2018;10(3):346-352. doi:<https://dx.doi.org/10.1159/000494078>
99. Plaquevent M, Greliak A, Pinard C, Duval-Modeste A-B, Joly P. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy. *Melanoma research*. 2019;29(3):311-312. doi:<https://dx.doi.org/10.1097/CMR.0000000000000555>
100. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(24):2162-2170. doi:<https://dx.doi.org/10.1200/JCO.2017.77.3184>
101. Nardin C, Borot S, Beaudoin M-A, et al. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. *Investigational new drugs*. 2019;37(2):375-377. doi:<https://dx.doi.org/10.1007/s10637-018-0659-9>
102. Smith MH, Bass AR. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. *Arthritis care & research*. 2019;71(3):362-366. doi:<https://dx.doi.org/10.1002/acr.23467>
103. Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. *Melanoma research*. 2019;29(1):102-106. doi:<https://dx.doi.org/10.1097/CMR.0000000000000543>
104. Tauber M, Cohen R, Laly P, Josselin L, Andre T, Mekinian A. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. *Clinical rheumatology*. 2019;38(2):601-602. doi:<https://dx.doi.org/10.1007/s10067-018-4373-y>
105. Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. *Journal for immunotherapy of cancer*. 2019;7(1):2. doi:<https://dx.doi.org/10.1186/s40425-018-0478-8>
106. Fixsen E, Patel J, Selim MA, Khetarpal M. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine. *The oncologist*. 2019;24(3):e103-e105. doi:<https://dx.doi.org/10.1634/theoncologist.2018-0531>
107. Lee J, Graham A, Sion A. Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2019;25(8):1867-1872. doi:<https://dx.doi.org/10.1177/1078155218822707>
108. Chanal J, Kramkimel N, Ratour C, Aractingi S, Guegan S, Avril M-F. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age. *Dermatology (Basel, Switzerland)*. 2019;235(3):219-224. doi:<https://dx.doi.org/10.1159/000492467>
109. Kim JM, Materin MA, Sznol M, et al. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. *Ophthalmology*. 2019;126(7):1058-1062. doi:<https://dx.doi.org/10.1016/j.ophtha.2019.01.031>
110. Leaf RK, Ferreri C, Rangachari D, et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. *American journal of hematology*. 2019;94(5):563-574. doi:<https://dx.doi.org/10.1002/ajh.25448>
111. Porambo ME, Sedarsky KE, Elliott EJ, Theeler BJ, Smith JK. Nivolumab-induced neuralgic amyotrophy with hourglass-like constriction of the anterior interosseous nerve. *Muscle & nerve*. 2019;59(6):E40-E42. doi:<https://dx.doi.org/10.1002/mus.26454>
112. Reed VA, Rizvi N. Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. *The oncologist*. 2019;24(6):730-734. doi:<https://dx.doi.org/10.1634/theoncologist.2018-0241>
113. Lou Y, Marin-Acevedo JA, Vishnu P, et al. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. *Immunotherapy*. 2019;11(7):577-584. doi:<https://dx.doi.org/10.2217/imt-2018-0128>
114. Berger M, Amini-Adle M, Crumbach L, Paubelle E, Dalle S. A case of immune thrombocytopenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. *European journal of cancer (Oxford, England : 1990)*. 2019;112:94-97. doi:<https://dx.doi.org/10.1016/j.ejca.2019.02.006>
115. Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. *Journal for immunotherapy of cancer*. 2019;7(1):112. doi:<https://dx.doi.org/10.1186/s40425-019-0583-3>
116. Schwab KS, Kristiansen G, Isaak A, Held SEA, Heine A, Brossart P. Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy. *Frontiers in oncology*. 2019;9:403. doi:<https://dx.doi.org/10.3389/fonc.2019.00403>
117. Wouters A, Durieux V, Kolivras A, Meert A-P, Sculier J-P. Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review. *Anticancer research*. 2019;39(6):3003-3008. doi:<https://dx.doi.org/10.21873/anticancer.13432>
118. Gill A, Perez MA, Perrone CM, Bae CJ, Pruitt AA, Lancaster E. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. *Journal of neuroimmunology*. 2019;334:576980. doi:<https://dx.doi.org/10.1016/j.jneuroim.2019.576980>

119. Veronesi G, Scarfi F, Misciali C, et al. An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus. *Anti-cancer drugs*. 2019;30(9):969-972. doi:<https://dx.doi.org/10.1097/CAD.0000000000000819>
120. Ryuzaki M, Tokuyama H, Uchiyama K, et al. Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports. *Clinical medicine insights Case reports*. 2019;12:1179547619853647. doi:<https://dx.doi.org/10.1177/1179547619853647>
121. Isami A, Uchiyama A, Shimaoka Y, Suzuki S, Kawachi I, Fujita N. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. *Rinsho shinkeigaku = Clinical neurology*. 2019;59(7):431-435. doi:<https://dx.doi.org/10.5692/clinicalneuro.cn-001270>
122. Bezinelli LM, Eduardo FP, Migliorati CA, et al. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2019;42(9):359-362. doi:<https://dx.doi.org/10.1097/CJI.0000000000000280>
123. Sidiropoulou P, Sgontzou T, Kostara I, et al. Nivolumab in non-small cell lung cancer: A novel case of an erythema annulare centrifugum-like eruption. *JAAD case reports*. 2019;5(7):572-575. doi:<https://dx.doi.org/10.1016/j.jdcr.2019.04.007>
124. Komiya K, Nakamura T, Abe T, et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. *Thoracic cancer*. 2019;10(9):1798-1804. doi:<https://dx.doi.org/10.1111/1759-7714.13149>
125. Noda T, Kageyama H, Miura M, Tamura T, Ito H. [A case of myasthenia gravis and myositis induced by pembrolizumab]. *Rinsho shinkeigaku = Clinical neurology*. 2019;59(8):502-508. doi:<https://dx.doi.org/10.5692/clinicalneuro.cn-001251>
126. Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. *Neurology*. 2019;93(11):e1093-e1103. doi:<https://dx.doi.org/10.1212/WNL.00000000000008091>
127. Galli G, Proto C, Cossa M, et al. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. *Tumori*. 2019;105(6):NP57-NP62. doi:<https://dx.doi.org/10.1177/0300891619872546>
128. Yuen C, Fleming G, Meyers M, Soliven B, Reznia K. Myasthenia gravis induced by avelumab. *Immunotherapy*. 2019;11(14):1181-1185. doi:<https://dx.doi.org/10.2217/imt-2019-0106>
129. Maetani Y, Nezu T, Ueno H, Aoki S, Hosomi N, Maruyama H. Steroid-responsive Nivolumab-induced Involuntary Movement with Anti-thyroid Antibodies. *Internal medicine (Tokyo, Japan)*. 2019;58(24):3577-3581. doi:<https://dx.doi.org/10.2169/internalmedicine.3200-19>
130. Shah N, Jacob J, Househ Z, Shiner E, Baird L, Soudy H. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. *Journal for immunotherapy of cancer*. 2019;7(1):247. doi:<https://dx.doi.org/10.1186/s40425-019-0727-5>
131. Blanchard A, Bouchard N. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. *Current oncology (Toronto, Ont)*. 2019;26(4):e571-e573. doi:<https://dx.doi.org/10.3747/co.26.4859>
132. Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. *Journal for immunotherapy of cancer*. 2019;7(1):269. doi:<https://dx.doi.org/10.1186/s40425-019-0723-9>
133. Kurokawa K, Hara M, Iwakami S-I, et al. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. *Internal medicine (Tokyo, Japan)*. 2019;58(22):3283-3287. doi:<https://dx.doi.org/10.2169/internalmedicine.2591-18>
134. Martinez-Domenech A, Garcia-Legaz Martinez M, Magdaleno-Tapiel J, Valenzuela-Onate C, Perez-Pastor G, Perez-Ferriols A. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy. *Dermatology online journal*. 2019;25(9)
135. Thapa B, Ali A, Nair R, Vashisht R, Calabrese C. A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature. *Case reports in rheumatology*. 2019;2019:1326734. doi:<https://dx.doi.org/10.1155/2019/1326734>
136. Reddy CA, Schneider BJ, Brackett LM, Tai AW. Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. *Immunotherapy*. 2019;11(18):1527-1531. doi:<https://dx.doi.org/10.2217/imt-2019-0121>
137. Sakoh T, Kanzaki M, Miyamoto A, et al. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. *BMC cancer*. 2019;19(1):1220. doi:<https://dx.doi.org/10.1186/s12885-019-6444-0>
138. Rkman D, Likic R, Bebek M, Gnjidic M, Gamulin M. Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report. *Croatian medical journal*. 2019;60(6):552-555.
139. Mitropoulou G, Daccord C, Sauty A, et al. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors. *Respiration; international review of thoracic diseases*. 2020;99(2):181-186. doi:<https://dx.doi.org/10.1159/000504968>

140. Le Aye L, Harris JB, Siddiqi I, Hagiya A. Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature. *Journal of hematology*. 2019;8(2):71-78. doi:<https://dx.doi.org/10.14740/jh507>
141. Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous pemphigoid. *JAAD Case Rep*. Apr 2019;5(4):362-364. doi:10.1016/j.jcdr.2019.02.008
142. Ahern E, Allen MJ, Schmidt A, Lwin Z, Hughes BGM. Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). *Asia-Pacific journal of clinical oncology*. 2020;doi:<https://dx.doi.org/10.1111/ajco.13350>
143. Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. *Journal for immunotherapy of cancer*. 2020;8(1)doi:<https://dx.doi.org/10.1136/jitc-2019-000380>
144. Cordes LM, Davarpanah NN, Reoma LB, et al. Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. *Clinical case reports*. 2020;8(1):24-32. doi:<https://dx.doi.org/10.1002/ccr3.2534>
145. Haddad N, Vidal-Trecan T, Baroudjian B, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. *The British journal of dermatology*. 2020;182(2):477-480. Comment in: *Br J Dermatol*. 2020 Feb;182(2):276-277; PMID: 31850528 [<https://www.ncbi.nlm.nih.gov/pubmed/31850528>]. doi:<https://dx.doi.org/10.1111/bjd.18124>
146. Thomas S, Bae C, Joy-Ann T, Traverse W. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2020;26(4):995-999. doi:<https://dx.doi.org/10.1177/1078155219877219>
147. Irifuku T, Satoh A, Tani H, Mandai K, Masaki T. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. *CEN case reports*. 2020;9(1):48-54. doi:<https://dx.doi.org/10.1007/s13730-019-00424-1>
148. Malek AE, Taremi M, Spallone A, Alvarez-Cardona JJ, Kontoyiannis DP. Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosuppressants due to checkpoint inhibitor-induced hepatitis. *The Journal of infection*. 2020;80(2):232-254. doi:<https://dx.doi.org/10.1016/j.jinf.2019.10.022>
149. Guo CW, Alexander M, Dib Y, et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. *European journal of cancer (Oxford, England : 1990)*. 2020;124:15-24. doi:<https://dx.doi.org/10.1016/j.ejca.2019.09.009>
150. Miyahara K, Noda T, Ito Y, et al. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. *Digestion*. 2020;101(1):60-65. doi:<https://dx.doi.org/10.1159/000504647>
151. Oki R, Hirakawa Y, Kimura H, et al. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma. *Internal medicine (Tokyo, Japan)*. 2020;59(7):977-981. doi:<https://dx.doi.org/10.2169/internalmedicine.3928-19>
152. Chan KK, Magro C, Shoushtari A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. *The oncologist*. 2020;25(2):140-149. doi:<https://dx.doi.org/10.1634/theoncologist.2019-0508>
153. Taillefer V-T, Pigeon M, Chen M, et al. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2020;26(6):1538-1543. doi:<https://dx.doi.org/10.1177/1078155220904147>
154. Xu Y, Cai Y, Zu J, et al. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report. *Immunotherapy*. 2020;12(3):175-181. doi:<https://dx.doi.org/10.2217/imt-2019-0090>
155. Subedi A, Williams SG, Yao L, et al. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. *JAMA network open*. 2020;3(2):e200032. doi:<https://dx.doi.org/10.1001/jamanetworkopen.2020.0032>
156. Mizuno K, Ito T, Ishigami M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. *Journal of gastroenterology*. 2020;55(6):653-661. doi:<https://dx.doi.org/10.1007/s00535-020-01677-9>
157. Rossi A, Magri F, Caro G, et al. Eosinophilic folliculitis of the scalp associated with PD-1/PDL1 inhibitors. *Journal of cosmetic dermatology*. 2020;19(12):3367-3370. doi:<https://dx.doi.org/10.1111/jocd.13388>
158. Robert L, Langner-Lemercier S, Angibaud A, et al. Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor. *Clinical lung cancer*. 2020;21(5):e474-e477. doi:<https://dx.doi.org/10.1016/j.clcc.2020.03.006>
159. Xing Q, Zhang Z-W, Lin Q-H, et al. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. *Annals of translational medicine*. 2020;8(5):250. doi:<https://dx.doi.org/10.21037/atm.2020.01.79>
160. Terashima T, Iwami E, Shimada T, et al. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report. *BMC pulmonary medicine*. 2020;20(1):104. doi:<https://dx.doi.org/10.1186/s12890-020-1150-x>

161. Daoussis D, Kraniotis P, Filippopoulou A, et al. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. *Rheumatology (Oxford, England)*. 2020;59(5):1041-1050. doi:<https://dx.doi.org/10.1093/rheumatology/kez361>
162. Liu X, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. *Thoracic cancer*. 2020;11(3):810-818. doi:<https://dx.doi.org/10.1111/1759-7714.13327>
163. Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, et al. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. *Journal of cutaneous pathology*. 2020;47(10):954-959. doi:<https://dx.doi.org/10.1111/cup.13739>
164. Ogawa K, Kaneda H, Kawamoto T, et al. Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. *Investigational new drugs*. 2020;38(6):1901-1905. doi:<https://dx.doi.org/10.1007/s10637-020-00947-w>
165. von Itzstein MS, Khan S, Popat V, et al. Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition? *The oncologist*. 2020;25(8):e1242-e1245. doi:<https://dx.doi.org/10.1634/theoncologist.2019-0911>
166. Leaver PJ, Jang HS-I, Vernon ST, Fernando SL. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. *BMJ case reports*. 2020;13(5)doi:<https://dx.doi.org/10.1136/bcr-2019-232920>
167. Samejima Y, Iuchi A, Kanai T, et al. Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. *Internal medicine (Tokyo, Japan)*. 2020;59(16):2003-2008. doi:<https://dx.doi.org/10.2169/internalmedicine.4550-20>
168. Nowosielski M, Di Pauli F, Iglseder S, et al. Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. *Neurology(R) neuroimmunology & neuroinflammation*. 2020;7(4)doi:<https://dx.doi.org/10.1212/NXI.0000000000000773>
169. Tanabe K, Kanzaki H, Wada T, et al. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report. *Medicine*. 2020;99(21):e20464. doi:<https://dx.doi.org/10.1097/MD.00000000000020464>
170. Ueki Y, Tanaka T, Hashimoto K, Kobayashi K, Fukuta F, Masumori N. [Durable Response after Discontinuation Due to Immune-Related Adverse Events in a Patient with Metastatic Clear Cell Renal Cell Carcinoma : A Case Report]. *Hinyokika kyo Acta urologica Japonica*. 2020;66(5):147-151. doi:https://dx.doi.org/10.14989/ActaUrolJap_66_5_147
171. Kambayashi Y, Fujimura T, Kuroda H, Otsuka A, Irie H, Aiba S. Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy. *Case reports in oncology*. 2020;13(1):474-477. doi:<https://dx.doi.org/10.1159/000506976>
172. Rizell M, Aberg F, Perman M, et al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. *Case reports in oncology*. 2020;13(1):478-484. doi:<https://dx.doi.org/10.1159/000507320>
173. Zarkavelis G, Mauri D, Karassa F, et al. The cancer immunotherapy environment may confound the utility of anti-TIF-1gamma in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. *Contemporary oncology (Poznan, Poland)*. 2020;24(1):75-78. doi:<https://dx.doi.org/10.5114/wo.2020.94727>
174. Hendrix A, Yeo A-E, Lejeune S, Seront E. Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor. *BMJ case reports*. 2020;13(6)doi:<https://dx.doi.org/10.1136/bcr-2020-235249>
175. Terrier B, Humbert S, Preta L-H, et al. Risk of scleroderma according to the type of immune checkpoint inhibitors. *Autoimmunity reviews*. 2020;19(8):102596. doi:<https://dx.doi.org/10.1016/j.autrev.2020.102596>
176. Murray-Brown W, Wilsdon TD, Weedon H, et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. *Journal for immunotherapy of cancer*. 2020;8(1)doi:<https://dx.doi.org/10.1136/jitc-2019-000281>
177. Parikh RA, Chaon BC, Berkenstock MK. Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series. *Ocular immunology and inflammation*. 2020;1-6. doi:<https://dx.doi.org/10.1080/09273948.2020.1766082>
178. Osaki M, Tachikawa R, Ohira J, Hara S, Tomii K. Anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. *Investigational new drugs*. 2021;39(1):251-255. doi:<https://dx.doi.org/10.1007/s10637-020-00974-7>
179. Bhattacharyya I, Chehal H, Migliorati C. Severe oral erosive lichenoid reaction to pembrolizumab therapy. *Oral surgery, oral medicine, oral pathology and oral radiology*. 2020;130(5):e301-e307. doi:<https://dx.doi.org/10.1016/j.oooo.2020.06.014>
180. Uner M, Alhasson B, Obhrai J, Bagnasco SM. ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab. *Virchows Archiv : an international journal of pathology*. 2021;478(4):801-804. doi:<https://dx.doi.org/10.1007/s00428-020-02882-w>
181. Todo M, Kaneko G, Shirotake S, et al. Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. *IJU case reports*. 2020;3(1):17-20. doi:<https://dx.doi.org/10.1002/iju5.12128>

182. Ueki Y, Suzuki M, Horikawa Y, et al. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer. *Thoracic cancer*. 2020;11(9):2731-2735. doi:<https://dx.doi.org/10.1111/1759-7714.13582>
183. Pundole X, Jones AL, Tetzlaff MT, et al. Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. *Immunotherapy*. 2020;12(17):1213-1219. doi:<https://dx.doi.org/10.2217/imt-2020-0108>
184. McClure T, Cui W, Asadi K, John T, Testro A. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. *BMJ open gastroenterology*. 2020;7(1)doi:<https://dx.doi.org/10.1136/bmjgast-2020-000487>
185. Iyer SG, Khakoo NS, Aitcheson G, Perez C. Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. *BMJ case reports*. 2020;13(9)doi:<https://dx.doi.org/10.1136/bcr-2020-235607>
186. Uchio N, Unuma A, Kakumoto T, et al. Pembrolizumab on pre-existing inclusion body myositis: a case report. *BMC rheumatology*. 2020;4:48. doi:<https://dx.doi.org/10.1186/s41927-020-00144-5>
187. Wong EYT, Yong MH, Yong KP, et al. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series. *Asia-Pacific journal of clinical oncology*. 2020;doi:<https://dx.doi.org/10.1111/ajco.13442>
188. Lin JS, Wang DY, Mamlouk O, et al. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. *Journal for immunotherapy of cancer*. 2020;8(2)doi:<https://dx.doi.org/10.1136/jitc-2020-001287>
189. Kullberg SA, Krug H, Gaddis K, Goldfarb N. Programmed cell death protein 1 inhibitor-induced recalcitrant mixed small and medium vessel vasculitis. *Dermatology online journal*. 2020;26(9)
190. Tanaka S, Asakawa R, Komuta K, et al. A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma. *Respiratory medicine case reports*. 2020;31:101266. doi:<https://dx.doi.org/10.1016/j.rmcr.2020.101266>
191. Patel V, Elias R, Formella J, et al. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. *Journal for immunotherapy of cancer*. 2020;8(2)doi:<https://dx.doi.org/10.1136/jitc-2020-001198>
192. Ziogas DC, Gkoufa A, Cholongitas E, et al. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. *Journal for immunotherapy of cancer*. 2020;8(2)doi:<https://dx.doi.org/10.1136/jitc-2020-001322>
193. Siciliano MA, Dastoli S, Apolito M, et al. Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report. *Frontiers in oncology*. 2020;10:579445. doi:<https://dx.doi.org/10.3389/fonc.2020.579445>
194. Ueki Y, Matsuki M, Kubo T, et al. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma. *IJU case reports*. 2020;3(6):266-269. doi:<https://dx.doi.org/10.1002/iju5.12211>
195. Yoshikawa Y, Imamura M, Yamaoka K, et al. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. *Clinical journal of gastroenterology*. 2021;14(1):283-287. doi:<https://dx.doi.org/10.1007/s12328-020-01287-1>
196. Onishi S, Tajika M, Bando H, et al. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. *Journal of medical case reports*. 2020;14(1):230. doi:<https://dx.doi.org/10.1186/s13256-020-02541-3>
197. Peng L, Mao Q-Q, Jiang B, et al. Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. *Frontiers in oncology*. 2020;10:549168. doi:<https://dx.doi.org/10.3389/fonc.2020.549168>
198. Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2021;16(3):483-485. doi:<https://dx.doi.org/10.1016/j.jtho.2020.11.003>
199. Paparoupa M, Stupperich S, Goerg-Reifenberg L, Wittig A, Schuppert F. Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma. *Case reports in gastroenterology*. 2020;14(3):554-560. doi:<https://dx.doi.org/10.1159/000511252>
200. Kanaoka K, Moriizumi K, Okada H, et al. Pembrolizumab-Induced Delayed-Onset Hepatitis. *Case reports in gastroenterology*. 2020;14(3):586-592. doi:<https://dx.doi.org/10.1159/000509953>
201. Wang R, Das T, Takou A. IgA nephropathy after pembrolizumab therapy for mesothelioma. *BMJ case reports*. 2020;13(11)doi:<https://dx.doi.org/10.1136/bcr-2020-237008>
202. Vogrig A, Muniz-Castrillo S, Joubert B, et al. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. *Neurology*. 2021;96(6):e866-e875. doi:<https://dx.doi.org/10.1212/WNL.0000000000011340>
203. Rosner S, Agrawal Y, Sun DQ, et al. Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. *Journal for immunotherapy of cancer*. 2020;8(2)doi:<https://dx.doi.org/10.1136/jitc-2020-001675>

204. Liu X, Liang X, Liang J, Li Y, Wang J. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review. *Frontiers in oncology*. 2020;10:530478. doi:<https://dx.doi.org/10.3389/fonc.2020.530478>
205. Scanvion Q, Béné J, Gautier S, et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. *Oncoimmunology*. 2020;9(1):1722022. doi:10.1080/2162402X.2020.1722022
206. Beninato T, Fuca G, Di Guardo L, et al. Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors. *Melanoma research*. 2021;31(2):178-180. doi:<https://dx.doi.org/10.1097/CMR.0000000000000715>
207. Okada K, Seki M, Yaguchi H, et al. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. *Journal of neurology*. 2021;268(2):680-688. doi:<https://dx.doi.org/10.1007/s00415-020-10213-x>
208. Bui AN, Hirner J, Singer SB, et al. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. *Clinical and experimental dermatology*. 2021;46(2):328-337. doi:<https://dx.doi.org/10.1111/ced.14449>
209. Pelaez Bejarano A, Montero Perez O, Inoriza Rueda A, Garrido Martinez MT. Interstitial nephritis with pembrolizumab: A case report and review. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2020;1078155220961553. doi:<https://dx.doi.org/10.1177/1078155220961553>
210. Gallo A, Talerico R, Novello L, et al. Collagenous colitis and atezolizumab therapy: an atypical case. *Clinical journal of gastroenterology*. 2021;14(1):165-169. doi:<https://dx.doi.org/10.1007/s12328-020-01276-4>
211. Goda S, Tsuji T, Matsumoto Y, et al. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. *Current problems in cancer*. 2020;100686. doi:<https://dx.doi.org/10.1016/j.currprobcancer.2020.100686>
212. Ruini C, Haas C, Mastnik S, et al. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2021;44(2):71-75. doi:<https://dx.doi.org/10.1097/CJI.0000000000000354>
213. Huntley RE, DeNiro K, Yousef J, Sheedy M, Dillon JK. Severe Mucositis Secondary to Pembrolizumab: Reports of Two Cases, Review of the Literature, and an Algorithm for Management. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*. 2020;doi:<https://dx.doi.org/10.1016/j.joms.2020.11.023>
214. Koch EAT, Nickel FT, Heinzerling L, Schulz YK, Berking C, Erdmann M. Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2021;44(3):114-117. doi:<https://dx.doi.org/10.1097/CJI.0000000000000353>
215. Suyama T, Hagihara M, Kubota N, Osamura Y, Shinka Y, Miyao N. Acquired amegakaryocytic thrombocytopenia after durvalumab administration. *Journal of clinical and experimental hematopathology : JCEH*. 2021;61(1):53-57. doi:<https://dx.doi.org/10.3960/jslrt.20047>
216. Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. *Journal of neuro-oncology*. 2021;doi:<https://dx.doi.org/10.1007/s11060-021-03695-w>
217. Honma Y, Shibata M, Gohda T, et al. Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab. *Internal medicine (Tokyo, Japan)*. 2021;doi:<https://dx.doi.org/10.2169/internalmedicine.6535-20>
218. Villarreal H, Dao KH. A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy. *Proceedings (Baylor University Medical Center)*. 2020;34(1):124-125. doi:<https://dx.doi.org/10.1080/08998280.2020.1824962>
219. Murray K, Floudas A, Murray C, et al. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. *BMJ case reports*. 2021;14(2)doi:<https://dx.doi.org/10.1136/bcr-2020-238851>
220. Domblides M, Geier M, Decroisette C, Descourt R. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report. *Thoracic cancer*. 2021;doi:<https://dx.doi.org/10.1111/1759-7714.13862>
221. Shahzad O, Thompson N, Clare G, Welsh S, Damato E, Corrie P. Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. *Therapeutic advances in medical oncology*. 2021;13:1758835921992989. doi:<https://dx.doi.org/10.1177/1758835921992989>
222. Kim ST, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor ME. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. *Immunotherapy*. 2021;13(6):465-475. doi:<https://dx.doi.org/10.2217/imt-2020-0272>
223. Maillard A, Pastor R, Merat R. Anti-PD-1-Induced Hidradenitis Suppurativa. *Dermatopathology (Basel, Switzerland)*. 2021;8(1):37-39. doi:<https://dx.doi.org/10.3390/dermatopathology8010007>
224. Sturmer SH, Lechner A, Berking C. Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2021;doi:<https://dx.doi.org/10.1097/CJI.0000000000000367>

225. Ogawa S, Kawakami H, Suzuki S, et al. Metachronous Esophageal Ulcers after Immune-mediated Colitis Due to Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review. *Internal medicine (Tokyo, Japan)*. 2021;doi:<https://dx.doi.org/10.2169/internalmedicine.6606-20>
226. Janssen JBE, Leow TYS, Herbschleb KH, et al. Immune Checkpoint Inhibitor-related Guillain-Barre Syndrome: A Case Series and Review of the Literature. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2021;doi:<https://dx.doi.org/10.1097/CJI.0000000000000364>
227. Williams KJ, Allen RC. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer. *J Neuroophthalmol*. Mar 01 2021;41(1):e71-e72. doi:10.1097/WNO.0000000000000927
228. Lin X, Deng H, Chen L, et al. Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. *Translational lung cancer research*. 2021;10(1):415-429. doi:<https://dx.doi.org/10.21037/tlcr-20-1258>